ORPHA:75327
North Carolina macular dystrophy
Also known as: CAPE dystrophy · CAPED · Central areolar pigment epithelial dystrophy · Central retinal pigment epithelial dystrophy · MCDR1 · NCMD · North Carolina macular dystrophy, retinal 1 · Progressive foveal dystrophy
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
1,639
Trials
0
Interventional, condition-specific
Researchers
1,087
Distinct authors in sample
Gene link
PRDM13
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A non- macular disorder of or onset characterized by loss of central vision, the accumulation of drusen in the macula and atrophy of photoreceptor cells with a variable at macular examination.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007630
- MeSH:C537835
- OMIM:136550
- UMLS:C0730294
Additional Mondo synonyms (5)
caped · central areolar pigment epithelial dystrophy · central retinal pigment epithelial dystrophy · macular dystrophy 1, North Carolina type · progressive foveal dystrophy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — PRDM13
- LiteraturePresent
1,639 matched papers (686 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PRDM13).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,639
1,639 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,639 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
686 in the last 10 years · low confidence
Phrase hits: 1,639 · MeSH hits: 0
Who's working on it?
1,087
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Small KW31 papers · 2026
Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA. small@jsei.ucla.edu
Papers in Europe PMC - 02Udar N11 papers · 2024
Molecular Insight Research Foundation, Glendale, California.
Papers in Europe PMC - 03
- 04Moore AT9 papers · 2025
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom; Ophthalmology Department, University of California San Francisco, San Francisco, California.
Papers in Europe PMC - 05Puech B7 papers · 2019
Service d'Exploration de la vision et Neuro-ophtalmologie CHRU, Lille, France.
Papers in Europe PMC - 06Arno G6 papers · 2024
Moorfields Eye Hospital NHS Trust, London, UK; UCL Institute of Ophthalmology, University College London, London, UK; Greenwood Genetic Center, Greenwood, SC, USA.
Papers in Europe PMC - 07Avetisjan J6 papers · 2023
Molecular Insight Research Foundation, Glendale and Los Angeles, CA, USA.
Papers in Europe PMC - 08Michaelides M6 papers · 2024
Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, United Kingdom. Electronic address: michel.michaelides@ucl.ac.uk.
Papers in Europe PMC - 09Webster AR6 papers · 2024
Moorfields Eye Hospital NHS Trust, London, UK; UCL Institute of Ophthalmology, University College London, London, UK. Electronic address: andrew.webster@ucl.ac.uk.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"North Carolina macular dystrophy" OR "CAPE dystrophy" OR "CAPED" OR "Central areolar pigment epithelial dystrophy" OR "Central retinal pigment epithelial dystrophy" OR "MCDR1" OR "North Carolina macular dystrophy, retinal 1" OR "Progressive foveal dystrophy" OR "macular dystrophy 1, North Carolina type"
MeSH descriptor terms unioned into the query: Macular dystrophy, retinal, 1, North Carolina type
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"North Carolina macular dystrophy" OR "CAPE dystrophy" OR "CAPED" OR "Central areolar pigment epithelial dystrophy" OR "Central retinal pigment epithelial dystrophy" OR "MCDR1" OR "North Carolina macular dystrophy, retinal 1" OR "Progressive foveal dystrophy" OR "macular dystrophy 1, North Carolina type" OR "Macular dystrophy, retinal, 1, North Carolina type" OR "PRDM13" OR "macular dystrophy, retinal" OR "hereditary macular dystrophy"
Recall-expansion terms: PRDM13, macular dystrophy, retinal, hereditary macular dystrophy
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: NCMD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1639) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T01:47:05.505Z